m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05919
 [1]
Non-coding RNA circMIRLET7BHG IGF2BP1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification ADAM10 ADAM10 IGF2BP1 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
m6A Target Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_MIRLET7BHG CircRNA View Details
Regulated Target Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Mechanistically, methyltransferase-like 3 (METTL3) enhanced Circ_MIRLET7BHG expression via m6A methylation, which enhanced Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) mRNA stability via interaction with IGF2BP1, thereby promoting AR by inducing epithelial barrier dysfunction.
Responsed Disease Allergic rhinitis ICD-11: CA08
 Disease Info 
Cell Process RNA stability
Cell infiltration, Cell apoptosis, inflammatory
In-vitro Model
 HNEpC (Human Nasal Epithelial Cells)
In-vivo Model Briefly, the mice were intraperitoneally injected with 25 μg OVA mixed with 1 mg aluminum hydroxide gel was intraperitoneally injected into mice once a week for three weeks. Subsequently, nostril challenge with 500 μg OVA was performed once a day for one week. The control mice were exposed to PBS (vehicle). LV-sh-NC or LV-sh-circMIRLET7BHG (1 × 107 TU/mL, GenePharma) were injected into mice via the tail vein two days before the nostril challenge.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Aderbasib Phase 1/2 [2]
Synonyms
INCB-007839; INCB-7839; Sheddase inhibitors (anticancer), Incyte; ADAM inhibitors (oral, cancer), Incyte
    Click to Show/Hide
MOA Modulator
External Link
CID: 16070111
TTD: D02CZF
 Compound Name IAI-100 Investigative [3]
Synonyms
ADAM inhibitors (cancer); IAI-102; INCB-3531; INCB-3619; A disintegrin and metalloprotease inhibitors (cancer), Incyte;ADAM inhibitors (cancer), Incyte; HER-2 sheddase inhibitors (cancer), Incyte
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 22 nM
External Link
CID: 11625778
TTD: D06EHW
 Compound Name ISIS 100748 Investigative [4]
External Link
TTD: D02CNG
 Compound Name ISIS 100742 Investigative [4]
External Link
TTD: D0J2VN
 Compound Name ISIS 100743 Investigative [4]
External Link
TTD: D0JV0I
 Compound Name ISIS 100749 Investigative [4]
External Link
TTD: D0Q6MK
 Compound Name PMID18068976C25 Investigative [4]
Synonyms
GTPL8568; BDBM50229655
    Click to Show/Hide
Activity IC50 = 6.2 nM
External Link
CID: 44447430
TTD: D0VI2A
 Compound Name ISIS 100750 Investigative [4]
External Link
TTD: D0X7FV
CA08: BackgroundAllergic rhinitis 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Conjugated Estrogens Approved [5]
Synonyms
Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt
    Click to Show/Hide
External Link
CID: 45357473
TTD: D0T0LU
 Compound Name Carbinoxamine Approved [6]
Synonyms
Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine
    Click to Show/Hide
External Link
CID: 2564
TTD: D00FGV
DrugBank: DB00748
References
Ref 1 CircMIRLET7BHG, upregulated in an m6A-dependent manner, induces the nasal epithelial barrier dysfunction in allergic rhinitis pathogenesis. Int Immunopharmacol. 2023 Dec;125(Pt B):111162. doi: 10.1016/j.intimp.2023.111162. Epub 2023 Nov 16.
Ref 2 Company report (Incyte)
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8679).
Ref 4 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 5 Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. Breast. 2008 Apr;17(2):172-9.
Ref 6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015